| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | Recombinant human full-length STAT3 protein was used as the immunogen for the STAT3 antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
STAT3 Antibody / Signal Transducer and Activator of Transcription 3 is an antibody targeting STAT3. Host: Mouse. Monoclonal. Clone: PCRP-STAT3-2F12. Format: Purified. Applications: ELISA, IHC-P.
Key elements and design rationale
- Target: STAT3.
- Immunogen: Recombinant human full-length STAT3 protein was used as the immunogen for the STAT3 antibody..
- Species reactivity: Human.
- Localization: Nucleus, Cytoplasm.
- Conjugate: Unconjugated (no label listed).
Biological background (from provided description)
The specificity of this monoclonal antibody to its intended target was validated by HuProtTM Array, containing more than 19,000, full-length human proteins. STAT3 is a member of the STAT protein family.
Common research applications
- IHC: tissue distribution assessment; interpret with matched controls.
Notes for experimental interpretation
- Account for isoforms, paralogs, and post-translational modifications when interpreting signal.
- Support specificity with biological controls (e.g., KO/KD where available) and technical controls (e.g., secondary-only/isotype).
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
